Practice-changing strategies in the treatment of esophageal cancer

For patients suffering from localized and advanced stage esophageal cancer, long-term outcomes remain poor. However, as already seen in other tumors, the introduction of immune checkpoint inhibitors has led to practice-changing results in the treatment of esophageal cancer. In this short review, five emerging studies are presented and discussed, which have changed standard of care in this disease.